Interesting comment posted on the latest bullish a
Post# of 72440
Quote:
Scootto
Comments (135) |+ Follow |Send Message
I have to say, I sell in the Rheumatology/Derm marketplace and the oral DMARD Otezla is worthless. Bad GI side effects, minimal efficacy,and what little efficacy it has diminishes over time. If PLURISOL has good efficacy this stock should pop. Also, preclinical trials show its better than MTX or methotrexate, the gold standard for DMARDS and first line therapy. POP goes the Weasel BC the Weasel goes POP! Here comes $20 min a share!!!
NEW | 04 May 2016, 12:54 PM